Suven Life Sciences Limited is an India-based holding company which is engaged in the business of bio-pharmaceutical i.e; manufacture and sale of bulk drugs and intermediaries.

Company’s segments include Manufacturing (CRAMS), which develops and produces bulk drugs and intermediates under contract manufacturing services; Services (DDDSS), which consists of collaborative research projects (CRP), clinical trials, and testing and analysis services, and Research and Development. Its products consist of active pharmaceutical ingredients (APIs), including Aripiprazole, Armodafinil, Calcium Acetate, Carprofen, Deferasirox, Doxofylline, Entacapone, Fenoprofen Calcium, Rosuvastatin Calcium, Sitagliptin Phosphate and Solifenacin succinate, and intermediates, including 2-nitro phenyl acetic acid and 3,4-dichlorobenzylamine.

Company is engaged in the drug discovery specializing in central nervous system (CNS)-based programs with over four of the molecules in pipeline under clinical phase of development.


Suven Life Sciences ResultsBSE Code : 530239
NSE Symbol : SUVEN
ISIN No. : INE495B01038
Industry :  Pharmaceuticals
Face Value : Rs. 1.00


If you are an investor who has shares of Suven Life Sciences or you are an stock market analyst then i am sure you might for Quarterly Results of Suven Life Sciences.

In this article you will find Q1, Q2, Q3, Q4 and FY 2016-17 Results of Suven Life Sciences. That’s not all, you can compare those results with previous year i.e., FY 2015-16 Results of Suven Life Sciences.

Suven Life Sciences Q1 Results 2016-17 :

Suven Life Sciences will announce its Q1 FY 2016-17 Results in the month of July 2016. We will update the table below once the results are announced.

(Values in Cr.) Q1 Standalone Q1 Consolidated
Revenue
Other Income
Total Income
Expenditure  –
Interest  –
Depreciation  –
PBT  –
Tax  –
Net Profit  –
Equity  –
EPS  –

Suven Life Sciences will announce its Q2 FY 2016-17 Results in the month of October 2016.

Suven Life Sciences will announce its Q3 FY 2016-17 Results in the month of January 2017.

Suven Life Sciences will announce its Q4 FY 2016-17 Results in the month of April 2017.

Suven Life Sciences will announce its FY 2016-17 Results in the month of April 2017.

Note : We will update the results table above as and when results are announced. Visit again.

Suven Life Sciences Previous Year’s Results (FY 2015-16) :

(Values in Cr.) Standalone Consolidated
Revenue 499.52 499.52
Other Income  19.35  19.35
Total Income  518.87  518.87
Expenditure  -376.27  -421.21
Interest  -5.42  -5.42
Depreciation  -16.72  -16.72
PBT  120.47  92.23
Tax  -25.50  -25.49
Net Profit  94.97  66.73
Equity  12.73  12.73
EPS  7.46  5.24

Note : If you like this information about Suven Life Sciences Quarterly Results, then please share it with all your friends, relatives and other investors on Facebook, Twitter, WhatsApp, Email, etc.